Growing global demand for non-invasive cellulite treatment

Consumers are now rooting for modern technical solutions to combat cellulite and are looking for non-herbal, non-invasive solutions.

As per a report by financialnewsmedia.com, cellulite affects 85% to 90% of all women worldwide. It was first described nearly 100 years ago, and has been the bane of women (and men) ever since. But to find a ‘cure’ or effective ‘solution’ the cause must be understood. Cellulite is a cosmetic problem, not a disease process. It isn’t harmful, but it is a serious cosmetic concern for those people who want to feel better about their appearance. According to dermatology sites, causes may be genetic, hormonal, or vascular in nature and may be related to the septa configuration in the subdermal tissue. Fibrosis at the dermal-subcutaneous junction as well as decreased vascular and lymphatic circulation also may be causative factors.

According to a report by Future Market Insights: “the market for non-invasive treatment is expected to reach a value of over US$ 1,900 million by the end of 2028, growing at a robust CAGR of 8.0% during the forecast period. This is followed by minimally invasive treatment, which secures the second position in the market. The market for minimally invasive treatment is expected to witness a growth rate of 7.8% during the projection period. Significant rise in the world’s middle-class population over the next few years will result in increase in the purchasing power and discretionary spending, which are the key factors responsible for the stability and growth of the market worldwide.”

Cellulite affects up to 90% of women and over a billion dollars per year is spent on treatment in the US. Key companies in this space include Soliton, Inc., Shockwave

invasive treatment, which secures the second position in the market. The market for minimally invasive treatment is expected to witness a growth rate of 7.8% during the projection period. Significant rise in the world’s middle-class population over the next few years will result in increase in the purchasing power and discretionary spending, which are the key factors responsible for the stability and growth of the market worldwide.”

Cellulite affects up to 90% of women and over a billion dollars per year is spent on treatment in the US. Key companies in this space include Soliton, Inc., Shockwave Medical, Inc., Pfizer Inc., Sesen Bio, Inc., and Boston Scientific Corporation. Soliton has announced its decision to move forward with a pivotal trial in cellulite after positive data from its proof of concept clinical trial for the reduction of cellulite (the “POC Trial”) confirmed.

“The market for non-invasive cellulite treatments is about $1 billion in the US, so it is clear that many women who are affected by the condition are interested in finding ways to reduce or eliminate it,” said Walter Klemp, co-founder and Executive Chairman of Soliton. “The very encouraging results of the POC Trial are driving our decision to launch the pivotal trial as quickly as possible and suggest we may be able to significantly improve the appearance of cellulite with a single completely non-invasive procedure. The procedure requires no recovery time and avoids the risks that go with even minimally invasive surgery.

Source: www.prnewswire.com

Write a Comment

view all comments

BOOK YOUR STAND

Please fill our short form.

Your Name (required)

Your Email (required)

Number (required)

Company Name (required)

Designation (required)

X